W0 2011/000721 A1 I||||||||||||||||||||||||||||||||||||||||||||||||||||||||| - Questel

wherein aj is 32 and J is a third generation 2,2'-bis(methoxyol)propanoic acid
(bis-MPA) based dendrimerforthe treatment and/or prevention of HIV (Human
Immunodeficiency Virus), Dengue, Ebola, Hepatitis C, SARS and
Mycobacterium tuberculosis infections.
For the purposes of a forth embodiment of the present invention, the disclosed
compounds may be formulated in a suitable effective amount together with
suitable pharmaceutically acceptable excipients according to the specific form
of administration and/or additives selected in the group comprising diluent,
solvents, bulking agents, fillers, reological modifier, stabilizers, binders,
lubricants, disintegrant, preservatives, pH adjusting agents, buffers,
antioxidant, chelating agents, plasticizer, polymers, emulsifiers, edulcorants,
flavoring agents, alone or in combination thereof, to give a pharmaceutical
preparation as per a further embodiment of the invention.
The preparations of the present invention may be administered by various
route of administration, such as, for instance, oral, including buccal or
sublingual administration; rectal; nasal; transdermal; vaginal; or parenteral,
including subcutaneous, intramuscular, intravenous or intradermal route or
topically.
In particular, for oral administration, they can be prepared in the form of hard or
soft capsules, tables, powders or granules; solutions syrups or suspensions in
aqueous or non-aqueous liquids; edible foams or whips; or either oil-in-water or
water-in-oil liquid emulsions. Alternatively, for nasal administration sprays or